-
INCORPORATING SPILLOVER EFFECTS IN COST-EFFECTIVENESS ANALYSIS: A CASE STUDY FOR FIRST LINE TREATMENT OF METASTATIC (STAGE IV) NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Mar 18, 2026, 21:38 PM -
COULD OPERATING-ROOM TIME DIFFERENCES FOR LITHOTRIPSY BE AN INDICATOR OF HEALTHCARE ACCESS?
Mar 18, 2026, 21:38 PM -
DISTANCE FROM HEALTH CARE FACILITY AND OTHER VARIABLES IMPACT TIME TO CELIAC DISEASE DIAGNOSIS
Mar 18, 2026, 21:38 PM -
COST COMPARISON OF ATEZOLIZUMAB IN CANADA FOR THE FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WITH HIGH PROGRAMMED DEATH-LIGAND 1 EXPRESSION
Mar 18, 2026, 21:38 PM -
ESTIMATING THE HEALTH OPPORTUNITY COST OF PUBLIC HEALTH EXPENDITURE IN KAZAKHSTAN: EMPIRICAL SUPPLY-SIDE COST-EFFECTIVENESS THRESHOLDS
Mar 18, 2026, 21:38 PM -
DO DATA SOURCES MATTER? COMPARING MARKET COST AND PAYER COST APPROACHES TO CALCULATING MEDICAL SPENDING MEASURES IN REAL-WORLD DATA
Mar 18, 2026, 21:38 PM -
PROBABILISTIC LINKING OF CLAIMS AND ELECTRONIC HEALTH RECORD (EHR) ENCOUNTERS USING THE FELLEGI-SUNTER STATISTICAL FRAMEWORK
Mar 18, 2026, 21:38 PM -
QUANTIFYING THE OPPORTUNITY: THE ECONOMIC AND COMMERCIAL CASE FOR ALS TREATMENT INNOVATION
Mar 18, 2026, 21:38 PM -
INCREASED RISK OF DIABETIC KETOACIDOSIS IN ADULTS WITH DELAYED DIAGNOSIS OF TYPE 1 DIABETES
Mar 18, 2026, 21:38 PM -
USE OF REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) IN PROSTATE CANCER (PC) ENABLES ON-DEMAND ACCESS TO PIVOTAL CLINICAL TRIAL EVIDENCE
Mar 18, 2026, 21:38 PM -
ECONOMIC BURDEN OF INCIDENT BRAIN METASTASES IN MEDICARE BENEFICIARIES WITH ALK+ METASTATIC NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF SUBCUTANEOUS MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN FOR UNITED STATES (US) PATIENTS WITH AUTOLOGOUS STEM CELL TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Mar 18, 2026, 21:38 PM -
ASSOCIATION OF FATIGUE AND ACUTE PAIN WITH HEALTH CARE RESOURCE UTILIZATION AND COSTS IN SICKLE CELL DISEASE IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
COMBINING DISCRETE CHOICE EXPERIMENT AND CONTINGENT VALUATION TO ESTIMATE WILLINGNESS-TO-PAY FOR LYME DISEASE VACCINE ATTRIBUTES IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
DISEASE PERCEPTION, QUALITY OF LIFE, AND MENTAL HEALTH OF NEWLY DIAGNOSED AND AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)-ELIGIBLE MULTIPLE MYELOMA PATIENTS FROM A TERTIARY CARE HOSPITAL IN CHINA: A CROSS-SECTIONAL SURVEY STUDY
Mar 18, 2026, 21:38 PM -
DISTINGUISHING AI FROM AUTOMATION IN HEOR: LESSONS FROM OTHER INDUSTRIES
Mar 18, 2026, 21:38 PM -
BRIDGING HER2 TESTING AND TREATMENT: REAL-WORLD EVIDENCE ACROSS 22 SOLID TUMORS
Mar 18, 2026, 21:38 PM -
NEUROLOGIST PREFERENCES FOR NEW MS TREATMENTS: IMPLICATIONS FOR MARKET ACCESS PRIORITIZATION IN THE UNITED STATES AND EUROPE
Mar 18, 2026, 21:38 PM -
FORMULARY EXCLUSIONS AND NON-ADHERENCE TO DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS IN MEDICARE PART D
Mar 18, 2026, 21:38 PM -
DOES ARTIFICIAL INTELLIGENCE IMPROVE OUTCOMES IN ACUTE ISCHEMIC STROKE CARE?
Mar 18, 2026, 21:38 PM
